From
$129.99
excl. VAT
4 Peptides listed
Growth Hormone Peptides groups four agent classes of the somatotropic axis: GHRH analogs, GHRPs, GH fragments, and full-length somatropin. Every product is HPLC-tested, labelled Research Use Only, and intended exclusively for in-vitro and preclinical research.
+ Buy
From
$124.99
excl. VAT
Stack Builder
GH-axis stack
GHRH analog, GHRP, GH fragment, and full-length somatropin are often run in separate experimental arms to cleanly separate pulsatile GH release, synergistic secretagogue effects, direct lipolysis, and anabolic IGF-1-mediated effects.
CJC
CJC
IPA
From
$109.99
excl. VAT
GHRH
Tesamorelin
GHRH-Analogon · Visceral-Fat
From
$109.99
excl. VAT
⌘ Quick compare
Peptides in Growth Hormone compared
Questions about Growth Hormone
Tesamorelin is a synthetic GHRH analog with an additional trans-3-hexenoyl group at the N-terminus that improves enzymatic stability. Research groups use it to study the pulsatile release of endogenous growth hormone and the downstream IGF-1 response. Typical study areas include visceral adipose tissue and HIV-associated lipodystrophy (Falutz et al., NEJM 2007; Stanley et al., JCEM 2019). Its plasma half-life is approximately 30 minutes, but the biological window is longer because the triggered GH pulse itself unfolds on a delayed timescale.
Background
Growth Hormone
What does the Growth Hormone category cover?
Growth Hormone groups research peptides that engage the somatotropic axis, the hormonal cascade that links the hypothalamus, the pituitary, and peripheral target tissues. GHRH analogs such as Tesamorelin and Sermorelin mimic hypothalamic growth-hormone-releasing hormone and stimulate pulsatile endogenous GH release from the pituitary, followed by a consecutive IGF-1 response. GHRPs such as Ipamorelin, Hexarelin, GHRP-2 and GHRP-6 act through the ghrelin receptor (GHS-R) and trigger GH secretion via a second, complementary pathway. GH fragments such as HGH Fragment 176-191 and AOD-9604 correspond to the C-terminal segment of human growth hormone and are studied for lipolytic mechanisms that operate independently of the IGF-1 pathway. HGH 191AA (somatropin) reproduces the complete 191-amino-acid sequence and engages the entire GH axis, driving JAK2/STAT5 signaling, hepatic IGF-1 induction, and peripheral lipolysis in one molecule. The category is built for preclinical work on GH pulsatility, fat metabolism, visceral-adipose models, protein synthesis, bone and muscle turnover, and interactions with other metabolic peptides in controlled experimental settings.
GHRH, GHRP, fragment and full-length compared
The four classes act at different points of the somatotropic axis and are therefore deliberately separated or combined in research. The overview below maps the peptides in this category to their points of action and typical research endpoints:
- GHRH analogs (Tesamorelin, Sermorelin, CJC-1295 no-DAC): bind the pituitary GHRH receptor and trigger pulsatile endogenous GH release. Very short plasma half-life, roughly 10 to 30 minutes. Endpoint: GH pulse and downstream IGF-1 response.
- GHRPs / ghrelin-receptor agonists (Ipamorelin, Hexarelin, GHRP-2, GHRP-6): bind the GHS-R and trigger GH secretion through a second pathway that synergizes with GHRH analogs. Half-life roughly 1 to 2 hours. Endpoint: synergistic GH release, selectivity over prolactin and cortisol.
- GH fragments (HGH Fragment 176-191, AOD-9604): reproduce the C-terminal lipolytic segment of growth hormone and act directly on the adipocyte without relevant IGF-1 elevation. Half-life roughly 2.5 to 3 hours. Endpoint: lipolysis and fat oxidation isolated from the IGF-1 pathway.
- Full-length somatropin (HGH 191AA): the complete 191-amino-acid sequence that dimerizes the GH receptor and activates JAK2/STAT5. Half-life roughly 20 minutes. Endpoint: the entire GH axis, with anabolic, lipolytic and counter-insulinic effects in one ligand.
Related guides